DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spotted fever — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpotted fever maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spotted fever is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
matrix metallopeptidase 7 (MMP7) — MMP7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2Y6D · 1.6 Å · ligand N-[(2S)-1-[4-(5-BROMOPYRIDIN-2-YL)PIPERAZIN-1-YL]SULFONYL-5-PYRIMIDIN-2-YL-PENTAN-2-YL]-N-HYDROXY-METHANAMIDE (TQJ). Experimental structure, not a prediction.
What the evidence adds up to
In 1984, Theodore E. Woodward stated that epidemiological clues and early clinical signs are the keys to treatment and reduced mortality in Rocky Mountain spotted fever; no drug or survival number was given in that abstract. A 1944 paper on Rocky Mountain spotted fever noted that supportive therapy had not been used as effectively as it might be, that hyperimmune antiserum was not widely used and was usually given too late, and that poorly directed parenteral therapy could be harmful. The same abstract reported that some physicians of wide experience had advised against transfusions and intravenous fluids, having observed harm from them.
A 1980 report of two patients with Rocky Mountain spotted fever said atypical manifestations led to delay in diagnosis and treatment; the authors advised that if the disease cannot be ruled out, therapeutic regimens should include appropriate antimicrobial coverage, but no specific drug or outcome numbers were provided. A 2005 case report of Mediterranean spotted fever in Hong Kong described a middle-aged man with persistent fever, headache, and rash whose daughter had similar symptoms three weeks earlier; the authors stated that early recognition could lead to early therapeutic intervention, decreased morbidity, and shortened hospital stay, but gave no drug names or quantitative results.
A 2010 review of Mediterranean spotted fever in returning travellers reported three patients with severe complications: one with meningoencephalitis, one with lung embolism, and one with septic shock and multi-organ failure. In published series, the rate of severe organ involvement ranged from 1% to 20%, though study designs were too variable for meaningful comparison. Meningoencephalitis and shock with multi-organ failure were the most frequent complications, and mortality of severe cases reached 20% in some series. The authors concluded that severe organ involvement is not infrequent and that early appropriate antibiotherapy is crucial, but no specific drug, regimen, or survival data from a controlled trial were given.
What is still missing is any randomised controlled trial of a repurposed drug for spotted fever, any standardised supportive care protocol against which a drug could be tested, and any patient stratification by severity or complication type that would allow a trial to detect a mortality benefit.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Infectious Diseases · 1984 · 40 citations
Rocky Mountain Spotted Fever: Epidemiological and Early Clinical Signs are Keys to Treatment and Reduced Mortality
AbstractJournal Article Rocky Mountain Spotted Fever: Epidemiological and Early Clinical Signs are Keys to Treatment and Reduced Mortality Get access Theodore E. Woodward Theodore E. Woodward Department of Medicine, University of Maryland School of Medicine, and the Veterans Administration Medical Center, Baltimore, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar The Journal of Infectious Diseases, Volume 150, Issue 4, October 1984, Pages 465–468, https://doi.org/10.1093/infdis/150.4.465 Published: 01 October 1984
Journal of Travel Medicine · 2010 · 33 citations · open access
Diversity of Life‐Threatening Complications due to Mediterranean Spotted Fever in Returning Travelers: Table 1
AbstractBACKGROUND: Mediterranean spotted fever (MSF) is a tick-borne infection caused by Rickettsia conorii conorii mainly endemic in the Mediterranean Basin. Although usually considered as a benign disease, severe forms of MSF have been sporadically reported. METHODS: We report on three patients who developed severe MSF complications after a stay in Morocco. Literature was reviewed to assess the frequency and pattern of MSF complications in the largest reported case series in endemic countries. RESULTS: Each of our three patients diagnosed with MSF presented with a different complicated course: one with meningoencephalitis, one with lung embolism and one with septic shock and multi organ failure. In published series, rate of complications (defined as severe organ involvement) ranged from 1% to 20%. However, study designs and settings were highly variable and did not allow for relevant comparisons. Meningoencephalitis and shock with multi organ failure were the most frequently observed complications. Mortality of severe course was up to 20% in some series. CONCLUSION: Severe organ involvement is not infrequent in patients with Mediterranean spotted fever and fatal outcome is regularly reported. Because presentations of complicated course may be extremely diverse, a high index of suspicion is required in febrile patients with potential exposure, in particular if skin rash and/or eschar are found. Early appropriate antibiotherapy is crucial to improve outcome.
AbstractSupportive therapy has not been as effectively used in Rocky Mountain spotted fever as it might be. Several misconceptions, including the idea that intravenous fluids are harmful, have been allowed to remain unchallenged in the literature. Specific therapy with hyperimmune antiserum is not widely used as yet and is usually given too late to be of greatest benefit. Before its efficacy can be evaluated, basic supportive therapy must be better standardized. The usual treatment of the disease consists in general supportive measures and the relief of symptoms. It is true that poorly directed or unwisely chosen parenteral supportive therapy may prove harmful. Because parenteral therapy has been given to poor advantage in some cases, statements such as the following have been made: In recent years, many physicians of wide experience with spotted fever have advised against transfusions and intravenous fluids. They have observed that patients receiving this type of treatment
AbstractTwo patients with Rocky Mountain spotted fever presented with atypical manifestations which led to a delay in diagnosis and treatment. Such clinical manifestations occurring in endemic areas during warm months should not eliminate consideration of the proper diagnosis. If RMSF cannot be ruled out, therapeutic regimens should include appropriate antimicrobial coverage.
The Pediatric Infectious Disease Journal · 2012 · 1 citations
Annular Rash Outbreak in a Family
AbstractA previously healthy 6-year-old female child presented to the outpatient clinic with a generalized erythematous, annular, slightly raised and mildly pruritic rash that was present primarily on the right upper arm for 1 week. She complained of low-grade fever (up to 37.9°C), myalgia and fatigue. One week previously, her primary physician had treated her with oral azithromycin and cephalexin for the rash. Despite this, the rash worsened, and lesions were present on the trunk, face and neck, sparing palms and soles. The patient denied respiratory symptoms, diarrhea, vomiting, headache, recent travel and tick bite exposure. Her medical history included only allergic rhinitis treated with diphenhydramine and montelukast. The patient’s mother and 15-year-old sister, both of whom had familial Mediterranean fever, developed a similar rash on their face, arms and trunk. In addition, the boyfriend of the 15-year-old sister and the playmate of the patient who frequently visited the home had begun to develop similar lesions. The family reported owning 1 rat, 3 cats and 3 dogs. They volunteered regularly in an animal shelter and had recently adopted a kitten found in a trash dumpster. The patient and the other family members had been in close contact with the kitten. When initially adopted, the kitten had an annular erythematous rash, cough, runny nose and hair loss, which was improving with antibiotics treatment. On examination, the patient was alert, oriented, afebrile and active with a pulse of 94 beats/min and blood pressure of 103/57 mm Hg. The patient had no neck stiffness, adenopathy, photophobia or organomegaly. She had extensive raised, erythematous, annular and papular crusting lesions on the trunk, neck, face and on the medial aspect of the upper extremities (see Fig., Supplemental Digital Content 1, https://links.lww.com/INF/B165). A few lesions were present on the lower extremities and back. There were no vesicles, ulcers or bullous lesions. No desquamation of skin was noted, and the palms and soles were free of lesions. The mother and sister had similar lesions. Complete blood count with a differential and serum electrolytes were all normal. Serologic testing of both the patient and her elder sister was negative for Rickettsia and Rocky Mountain spotted fever IgG and IgM. Typhus fever group AB IgG and IgM were <1:64. An office procedure was performed that confirmed the diagnosis. For denouement see p. 1002.
Hong Kong Journal of Emergency Medicine · 2005 · 0 citations · open access
Persistent Fever and Exanthema in a Family: A Case Report of Mediterranean Spotted Fever
AbstractMediterranean spotted fever (also called Boutonneuse fever) is a notifiable disease in Hong Kong, but its diagnosis can be difficult. We report a case of Mediterranean spotted fever in a middle-aged man who presented with persistent fever, headache, and skin rash. Three weeks ago, his daughter had similar presentations. With a history of similar clinical presentation within family members, the possibility of potential exposure to a common disease vector should be suspected. Establishing an early diagnosis may be possible if this important history is obtained. Early recognition of this disease may lead to early therapeutic intervention, resulting in decreased morbidity and shortened duration of hospital stay.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
